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Abstract: An efficient one-pot synthesis of 2-thioxopyrimido[4,5-b]quinoline 3a,b has been accomplished from a three-component reaction of 
6-aminothiouracil, cyclohexanone and aromatic aldehyde under microwave irradiation. Compound 3a,b was used as a key intermediate for the 
synthesis of S- and C-nucleoside analogs of types, 5-(4-fluorophenyl / 4-anisyl)-2-S-(-D-ribofuranosyl / arabinofuranosyl)-6,7,8,9-tetrahydro-3H-
pyrimido[4,5-b]quinolin-4-one (6a–d) and 5-(4-fluorophenyl / 4-anisyl)-2-S-(-D-gluco / galactopyranosyl)-6,7,8,9-tetrahydro-3H-pyrimido[4,5-
b]quinolin-4-one (8a–d). Also. the 2-hydrazino compounds 9a,b were used for the synthesis of 3-(glycosyl)-6-(4-substituted phenyl)-7,8,9,10-
tetrahydro[1,2,4]triazolo[4',3':1,2]pyrimido[4,5-b]quinoline-5-(1H)-one (11a–d and 13a–d). The title compounds were investigated for anti-
inflammatory and anticancer activities. Compounds 11a exhibited the comparable anti-inflammatory activity (83.4 %) to the standard drug 
Indomethacin (85.2 %). 5-(4-Fluorophenyl)-2-S-(-D-ribofuranosyl)-6,7,8,9-tetrahydro-3H-pyrimido[4,5-b]quinolin-4-one 6a and 3-(ribosyl)-5-
(4-fluorophenyl)-7,8,9,10-tetrahydro[1,2,4]triazolo[4',3':1,2]pyrimido[4,5-b]quinolin-5-one (13a) exhibited the maximum cytotoxic effect 
against the three human cancer cell lines with inhibitory effects higher than the reference doxorubicin. 
 





ANCER disease is a major worldwide problem. In the 
new millennium, rapid progress has been made in the 
area of a cancer cell, it has become clear that inflammation 
has an essential role in increased cancer risk.[1,2] The 
process of development of cancers may be due to 
inflammatory cells, in addition to a variety of mediators, 
like cytokines, chemokines and enzymes.[3] 
 Oxidative stress is an important mechanism in the 
pathogenesis of many diseases including cancer. The 
generation of reactive oxygen species (ROS) with 
consecutive DNA damage is an initial step in carcinogenesis 
induced by inflammatory processes.[4] ROS is generated 
either via inflammatory cytokines or via cytochrome P-450 
2E1 induction and may lead to lipid peroxidation. 
Chemokines and pro-inflammatory cytokines as 
interleukin(IL)-6 and IL-1α can favor the growth of tumor 
while the treatment with NSAIDS can minimize cancer 
incidence,[5] so there is a strong relation between cancer 
and inflammation. 
 Some of the pro-inflammatory factors such as 
reactive oxygen species, prostaglandin E2(PGE2) and tumor 
necrosis factor α (TNF α) are among molecules that play a 
major role in suppressing inflammation.[6] Nonsteroidal 
anti-inflammatory drugs (NSAIDS) have inhibitory activity 
toward cyclooxygenase-1(COX-1) and cyclooxygenase-2 
(COX-2).[7] NSAIDS suppress transcription factor NF-kB 
which regulates COX-2 and inhibits the tumor cell.[8] 
Quinoline occupies the catalytic split of human DNA repair 
O6-alkylguanine DNA alkyltransferase, by acting as analogs 
of the O6-guanine moiety in the natural substrate, and 
reaching the catalytic residue Cys145.[9] Furthermore, 
pyrimidine and fused heterocyclic pyrimidine derivatives 
show anti-inflammatory and anticancer activities,[10] so the 
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pyrimidoquinolines are considered to be promising nuclei 
for anticancer drug development. In addition to the wide 
range of biological activity of quinoline and pyrimido-
quinoline derivatives, these compounds have attracted a 
great deal of attention in the field of medicinal chemistry. 
Quinoline and pyrimidoquinoline derivatives are an 
important class of therapeutically useful antibacterial 
drugs,[11–14] anticancer,[15,16] antioxidant, analgesic and anti-
inflammatory activities,[17–19] antiallergic,[20] microsomal 
prostaglandin E synthase-1 (mPGES-1) inhibitor.[21] Also, 
some of these derivatives showed antimalarial activity.[22] 
 Microwave mediated multi-component reactions 
constitute an especially attractive synthetic strategy for 
rapid and efficient library generation because products 
are formed in a single step and diversity can be achieved 
by varying the reacting components. In continuation of 
our efforts towards multi-component reactions,[12] we 
report herein a conventional and microwave rapid 




Melting points were determined on griffin apparatus. The 1H 
NMR and 13C NMR spectra were recorded on a JEOL EX-300 
and JEOL ECA-500 (Japan). Chemical shifts were expressed in 
ppm relative to SiMe4 as internal standard in DMSO-d6 as a 
solvent. IR spectra were recorded as KBr pellets on a 
spectrometer (Perkin-Elmer 1430, USA) (National Research 
Centre and Department of Chemistry, Cairo University). Mass 
spectra were run at 70 eV on HP- 5988A mass spectrometer 
(Micro-analytical Centre, Cairo University). Elemental 
analyses were done on a model 2400 CHNSO analyser (Perkin 
Elmer, USA). All the values were within ±0.4 % of the 
theoretical values. Thin layer chromatography (chloroform / 
methanol, 8 : 2) indicated the formation of pure compounds. 
Cyclohexanone, 6-aminothiouracil, aldehydes and 1-bromo-
2,3,5-tri-O-acetyl-α-D-arabinofuranose, 2,3,5-tri-O-benzoyl-
-D-ribofuranosyl bromide, 2,3,4,6-tetra-O-acetyl-α-D-gluco-, 
galactopyranosyl bromide, chemicals and solvents were 
purchased from Sigma-Aldrich (USA). The biological activities 
were screened in Pharmacological Unit, National Research 




A mixture of cyclohexanone (0.01 mol), aryl aldehyde  
(0.01 mol) and 6-aminothiouracil (0.01 mol) was 
irradiated in a domestic microwave for 15 min. The 
reaction mixture was cooled, the precipitate was filtered 
off, washed with ethanol, dried and crystallized from DMF 
to produce (3a,b). 
5-(4-FLUOROPHENYL)-2-THIOXO-3,6,7,8,9-PENTAHYDRO-
1H-PYRIMIDO[4,5-b]QUINOLIN-4-ONE (3a) 
with p-florobenzaldehyde, as yellow powder in a 89 % yield, 
mp 315–317 °C. IR (KBr, cm–1) 3345, 1687 ;1H NMR (DMSO-
d6, ppm) δ: 1.50–1.60 (m, 2H, CH2), 1.61–1.76 (m, 2H, CH2), 
2.18 (t, 2H, CH2), 2.88 (t, 2H, CH2), 7.13 (d, 2H, phenyl, J = 
8.6 Hz), 7.47 (d, 2H, phenyl, J = 8.6 Hz), and 8.21, 12.22 (2br 
s, 2NH, D2O exchangeable); MS (m / z), 327 (M+, 78 %); 
C17H14FN3OS (327.3) calcd. C: 62.30, H: 4.31, N: 12.83; 




With p-anisaldehyde, as white powder in a 86 % yield, mp 
301–302 °C. IR (KBr, cm–1) 3400, 1683; 1H NMR (DMSO-d6, 
ppm) δ: 1.52–1.61 (m, 2H, CH2), 1.63–1.79 (m, 2H, CH2), 
2.23 (t, 2H, CH2), 2.91 (t, 2H, CH2), 3.89 (s, 3H, OCH3), 7.23 
(d, 2H, phenyl, J = 8.4 Hz), 7.50 (d, 2H, phenyl, J = 8.5 Hz), 
and 8.10, 11.30 (2br s, 2NH, D2O exchangeable). 13C.NMR: 
22.29, 23.56, 23.90, 24.78 (4CH2), 53.77 (OCH3), 121.6–
154.8 (11C-Ar), 167.6 (C-2-pyrimidine), 168.1 (CO); MS  
(m / z), 303 (M+, 83 %); C18H17N3O2S (303.3) calcd. C: 59.38, 




To a warm ethanolic potassium hydroxide solution 
(prepared by dissolving 0.01 mol of potassium hydroxide in 
30 mL absolute ethanol) was added compound 3a,b  
(0.01 mol), the heating was continued for 30 min, the 
mixture was allowed to cool to room temperature and 
methyl iodide (0.12 mol) was added. The mixture was 
stirred under reflux for 3 h, cooled to room temperature, 
and poured onto cold water (100 mL). The solid 
precipitated was filtered off, washed with water and dried, 




Yellow crystals, in a 79 % yield; mp 264-266 oC. IR (KBr, cm–1) 
3354, 1687; 1H NMR (DMSO-d6, ppm) δ:1.49–1.57 (m, 2H, 
CH2), 1.60–1.74 (m, 2H, CH2), 2.17 (t, 2H, CH2), 2.52 (s, 3H, 
S-CH3), 2.84 (t, 2H, CH2), 7.14 (d, 2H, phenyl), 7.46 (d, 2H, 
phenyl) and 9.45 (br s, NH, D2O exchangeable). MS (m / z), 
341 (M+, 69 %); C18H17N3O2S (303.3) calcd. C: 63.32, H: 4.72, 




Pale yellow crystals, in a 74 % yield; mp 243-245 oC. IR (KBr, 
cm–1) 3354, 1687; 1H NMR (DMSO-d6, ppm) δ: 1.48–1.56 
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(s, 3H, S-CH3), 2.76 (t, 2H, CH2), 3.78 (s, 3H, OCH3), 7.11 (d, 
2H, phenyl), 7.67 (d, 2H, phenyl) and 9.30 (br s, NH, D2O 
exchangeable). MS (m / z), 337 (M+, 56 %); C19H19N3OS 
(337.4) calcd. C: 67.62, H: 5.67, N: 12.45; found C 67.60, H: 
5.63, N: 12.42. 




To a solution of 3a,b (0.01 mol) in aqueous potassium 
hydroxide (0.01 mol) in distilled water (5 mL) a solution of 
1-bromo-2,3,5-tri-O-acetyl-α-D-arabinofuranose / 2,3,5-tri-
O-benzoyl--D-ribofuranosyl bromide or 2,3,4,6-tetra-O-
acetyl-α-D-gluco- and galactopyranosyl bromide (0.015 mol) 
in acetone (40 mL) was added. The reaction mixture was 
stirred at room temperature for 15–24 h (under TLC 
control). The solvent was evaporated under reduced 
pressure at 40 °C, and the crude product was filtered off 
and washed with distilled water to remove KBr formed. The 
product was dried, and crystallized from the ethanol to 





It was obtained from 3a and 2,3,5-tri-O-benzoyl--D-
ribofuranosyl bromide, as pale yellow powder in a 67 % 
yield; mp 289–291 °C. IR ( KBr, cm–1) 3379, 1730, 1689, 1H 
NMR (DMSO-d6, ppm) δ: 1.50–1.58 (m, 2H, CH2), 1.62–1.75 
(m, 2H, CH2), 2.25 (t, 2H, CH2), 2.78 (t, 2H, CH2), 4.09 (m, H-
4'), 4.19 (m, H-5', H-5"), 5.30 (m, H-3'), 5.38 (m, H-2'), 6.83 
(d, J = 3.67 Hz, H-1'), 7.00-7.09 (m, 6H, phenyl), 7.17 (d, 2H, 
phenyl), 7.49–7.65 (m, 9H, phenyl), 8.00 (d, 2H, phenyl), 
and 9.80 (brs, NH, D2O exchangeable). 13C.NMR: 23.08, 
23.11, 23.62, 24.51 (4CH2), 61.40 (C-5'), 66.23(C-3'), 68.84 
(C-2'), 70.19 (C-4'), 84.78 (C-1'), 121.3-155.6 (29 C-Ar), 
159.5 (C-2-pyrimidine), 167.5 (CO), 169.9, 170.7, 173.4 
(3CO). MS (m / z), 771 (M+, 24 %); C43H34FN3O8S (771.7) 






It was obtained from 3b and 2,3,5-tri-O-benzoyl--D-
ribofuranosyl bromide; as pale yellow powder. in a 70 % 
yield; mp 278–280 °C. IR (KBr, cm–1) 3360, 1726, 1686, 1H 
NMR (DMSO-d6, ppm) δ: 1.48–1.56 (m, 2H, CH2), 1.60–1.73 
(m, 2H, CH2), 2.19 (t, 2H, CH2), 2.76 (t, 2H, CH2), 3.78 (s, 3H, 
OCH3), 4.11 (m, H-4'), 4.18 (m, H-5', H-5"), 5.28 (m, H-3'), 
5.36 (m, H-2'), 6.90 (d, J = 3.67 Hz, H-1'), 6.96–7.11 (m, 6H, 
phenyl), 7.18 (d, 2H, phenyl), 7.56–7.70 (m, 9H, phenyl), 
8.04 (d, 2H, phenyl), and 9.55 (brs, NH). 13C.NMR: 23.10, 
23.14, 23.67, 24.59 (4CH2), 55.09 (OCH3), 60.56 (C-5'), 67.19 
(C-3'), 69.04 (C-2'), 70.23 (C-4'), 85.67 (C-1'), 120.6-155.4 
(29 C-Ar), 159.2 (C-2-pyrimidine), 165.8 (CO), 170.2, 171.3, 
173.8 (3CO). MS (m / z), 783 (M+, 15 %); C44H37N3O9S (783.8) 






It was obtained from compound 3a (0.01 mol) and 2,3,5-tri-
O-acetyl-α-D-arabinofuranosyl bromide (0.01 mol) as yellow 
powder, in a 58 % yield; mp 217–219 °C. IR (KBr, cm–1) 3320, 
1710, 1689, 1H NMR (DMSO-d6, ppm) δ: 1.51–1.59 (m, 2H, 
CH2), 1.61–1.74 (m, 2H, CH2), 2.16 (t, 2H, CH2), 2.19–2.31 
(3s, 9H, 3CH3CO), 2.81 (t, 2H, CH2), 3.55 (m, 2H, H-5', H-5"), 
3.71 (m, 1H, H-4'), 3.98 (m, 1H, H-3'), 4.21 (m, 1H, H-2'), 
4.61 (d, 1H, J = 3.74 Hz, H-1'), 7.21 (d, 2H, phenyl), 8.07 (d, 
2H, phenyl), and 9.70 (brs, NH, D2O exchangeable). MS (m / z), 
585 (M+, 34 %); C28H28FN3O8S (585.6) calcd. C: 57.42, H: 





It was obtained from compound 3b (0.01 mol) and 2,3,5-tri-
O-acetyl-α-D-arabinofuranosyl bromide (0.01 mol) as yellow 
powder, in a 69 % yield; mp 199–201 °C. IR (KBr, cm–1) 3360, 
1720, 1686.1H NMR (DMSO-d6, ppm) δ: 1.45–1.50 (m, 2H, 
CH2), 1.57–1.65 (m, 2H, CH2), 2.18 (t, 2H, CH2), 2.22–2.35 
(3s, 9H, 3CH3CO), 2.83 (t, 2H, CH2), 3.52 (m, 2H, H-5', H-5"), 
3.67 (m, 1H, H-4'), 3.78 (s, 3H, OCH3), 3.96 (m, 1H, H-3'), 
4.24 (m, 1H, H-2'), 4.63 (d, 1H, J = 3.71 Hz, H-1'), 7.23 (d, 2H, 
phenyl), 8.12 (d, 2H, phenyl), and 9.45 (brs, NH). 13C.NMR: 
22.89, 23.17, 23.91, 25.21 (4CH2), 53.78 (OCH3), 60.78 (C-
5'), 66.45 (C-3'), 69.17 (C-2'), 70.35 (C-4'), 85.74 (C-1'), 
120.4-155.8 (29 C-Ar), 158.7 (C-2-pyrimidine), 166.3 (CO), 
170.3, 171.7, 174.3 (3CO). MS (m / z), 597 (M+, 25 %); 
C29H31N3O9S (597.6) calcd. C: 58.28, H: 3.23, N: 7.03; found 





It was obtained from compound 3a (0.01 mol) and 2,3,4,6-
tetra-O-acetyl-α-D-glucopyranosyl bromide (0.01 mol) as 
pale yellow powder, in a 73 % yield; mp 219–221 °C. IR (KBr, 
cm–1) 3300, 1692,1720.1H NMR (DMSO-d6, ppm) δ: 1.44–
1.58 (m, 2H, CH2), 1.55–1.63 (m, 2H, CH2), 2.08 (t, 2H, CH2), 
2.15–2.29 (4s, 12H, 4CH3CO), 2.72 (t, 2H, CH2), 3.92 (m, 1H, 
H-5' ), 4.20 (m, 2H, H-6' , H-6" ), 5.07 (t, 1H, H-4' ), 5.11 (m, 
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H-1'), 7.20 (d, 2H, J = 8.5 Hz, phenyl), 7.98 (d, 2H, J = 8.5 Hz, 
phenyl), 10.00 (br, NH, D2O exchangeable). MS (m / z), 657 
(M+, 56 %); C31H32FN3O10S (657.6) calcd. C: 56.61, H: 4.90, 





It was obtained from compound 3b (0.01 mol) and 2,3,4,6-
tetra-O-acetyl-α-D-glucopyranosyl bromide (0.01 mol) as 
pale yellow powder, in a 68 % yield; mp 236–238 °C. IR (KBr, 
cm–1) 3320, 1687, 1727.1H NMR (DMSO-d6, ppm) δ: 1.47–
1.54 (m, 2H, CH2), 1.58–1.67 (m, 2H, CH2), 2.10 (t, 2H, CH2), 
2.16–2.32 (4s, 12H, 4CH3CO), 2.80 (t, 2H, CH2), 3.83 (s, 
OCH3), 3.92 (m, 1H, H-5'), 4.21 (m, 2H, H-6' , H-6"), 5.05 (t, 
1H, H-4'), 5.14 (m, 1H, H-2' ), 5.46 (t, 1H, J = 9.42 Hz, H-3' ), 
5.69 (d,1H, J =10.6, H-1' ), 7.23 (d, 2H, J =8.5 Hz, phenyl), 
7.88 (d, 2H, J = 8.5 Hz, phenyl), 10.15 (br, NH, D2O ex-
changeable). MS (m / z), 669 (M+, 49 %); C32H35N3O11S 
(669.7) calcd. C: 57.38, H: 5.26, N: 6.27; found C 57.40, H: 





It was obtained from compound 3a (0.01 mol) and 2,3,4,6-
tetra-O-acetyl-α-D-galactopyranosyl bromide (0.01 mol) as 
pale yellow powder, in a 70 % yield; mp 193–195 °C. IR (KBr, 
cm–1) 3310, 1682, 1720.1H NMR (DMSO-d6, ppm) δ: 1.50–
1.57 (m, 2H, CH2), 1.59–1.69 (m, 2H, CH2), 2.12 (t, 2H, CH2), 
2.15–2.31 (4s, 12H, 4CH3CO), 2.85 (t, 2H, CH2), 3.96 (m, 1H, 
H-5' ), 4.22 (m, 2H, H-6', H-6"), 5.07 (t, 1H, H-4'), 5.16 (m, 
1H, H-2'), 5.49 (t, 1H, J = 9.40 Hz, H-3'), 5.72 (d,1H, J = 9.8, 
H-1'), 7.23 (d, 2H, J = 8.6 Hz, phenyl), 7.90 (d, 2H, J = 8.6 Hz, 
phenyl), 9.70 (br, NH, D2O exchangeable). MS (m / z), 
657(M+, 53 %); C31H32FN3O10S (657.6) calcd. C: 56.61, H: 





It was obtained from compound 3b (0.01 mol) and 2,3,4,6-
tetra-O-acetyl-α-D-galactopyranosyl bromide (0.01 mol) as 
pale yellow powder, in a 71 % yield; mp 247-249 oC. IR (KBr, 
cm–1) 3310, 1682, 1720.1H NMR (DMSO-d6, ppm) δ: 1.50–
1.57 (m, 2H, CH2), 1.59–1.69 (m, 2H, CH2), 2.12 (t, 2H, CH2), 
2.15–2.31 (4s, 12H, 4CH3CO), 2.85 (t, 2H, CH2), 3.96 (m, 1H, 
H-5' ), 4.22 (m, 2H, H-6', H-6"), 5.07 (t, 1H, H-4'), 5.16 (m, 
1H, H-2'), 5.49 (t, 1H, J = 9.40 Hz, H-3'), 5.72 (d,1H, J = 9.8, 
H-1'), 7.23 (d, 2H, J = 8.6 Hz, phenyl), 7.90 (d, 2H, J = 8.6 Hz, 
phenyl), 9.70 (br, NH, D2O exchangeable). MS (m / z), 657 
(M+, 53 %); C32H35N3O11S (669.7) calcd. C: 57.38, H: 5.26, N: 
6.27; found C 57.36, H: 5.27, N: 6.24. 
General Procedure of Deacetylated  
S-Glycosides of 5-Aryl-6,7,8,9-
tetrahydro-3H-pyrimido-[4,5-b]quinolin-
4-one (6a–d and 8a–d) 
Dry gaseous ammonia was passed through a solution of 
acetylated compound 5a–d or 7a–d (1.0 mmol) in dry 
methanol (20 mL) at room temperature for 10 min. The 
mixture was stirred overnight (followed by TLC). The 
resulting mixture was then evaporated under reduced 
pressure to afford a solid residue that was crystallized 
from ethanol to afford 5-(4-flurophenyl / 4-anisyl)-2-S-(-
D-ribofuranosyl / arabinofuranosyl)-6,7,8,9-tetrahydro-3H-
pyrimido[4,5-b]quinolin-4-one (6a–d) and 5-(4-flurophenyl 
/ 4-anisyl)-2-S-(-D-gluco /  galactopyranosyl)-6,7,8,9-
tetrahydro-3H-pyrimido[4,5-b]quinolin-4-one (8a-d), as a 




Yield 52 %; mp 261–263 °C. IR (KBr, cm–1) 3400, 3320, 1674. 
1H NMR (DMSO-d6, ppm) δ: 1.45–1.55 (m, 2H, CH2), 1.56–
1.63(m, 2H, CH2), 2.18 (t, 2H, CH2), 2.86 (t, 2H, CH2), 3.87 
(m, H-5', H-5"), 4.16 (m, H-4'), 4.83 (t, H-2'), 5.19 (t, J = 5.41 
Hz, J = 4.94 Hz, OH-C(5'), 5.25 (d, J = 4.51 Hz, OH-C(3'), 5.46 
(d, J = 5.90 Hz, OH-C(2'), 5.68 (t, J = 9.83 Hz, H-3'), 6.83 (d,  
J = 5.63 Hz, H-1'), 7.18 (d, 2H, phenyl), 8.11 (d, 2H, phenyl), 
10.16 (br, NH, D2O exchangeable). MS (m / z), 459 (M+, 45 %); 
C22H22FN3O5S (459.5) calcd. C: 57.50, H: 4.82, N: 9.14; found 




Yield 59 %; mp 241–243 °C. IR (KBr, cm–1) 3432, 3305, 1669. 
1H NMR (DMSO-d6, ppm) δ: 1.46–1.53 (m, 2H, CH2), 1.59–
1.68 (m, 2H, CH2), 2.14 (t, 2H, CH2), 2.83 (t, 2H, CH2), 3.76 
(s, OCH3), 3.89 (m, H-5', H-5"), 4.17 (m, H-4"), 4.82 (t, H-2'), 
5.19 (t, J = 5.43 Hz, J = 4.98 Hz, OH-C(5'), 5.24 (d, J = 4.47 
Hz, OH-C(3'), 5.43 (d, J = 5.92 Hz, OH-C(2'), 5.69 (t, J = 9.80 
Hz, H-3'), 6.85 (d, J = 5.60 Hz, H-1'), 7.22 (d, 2H, phenyl), 
8.10 (d, 2H, phenyl), 10.26 (br, NH, D2O exchangeable), 13C 
NMR: 21.19, 22,75, 23.40, 24.53 (4CH2), 56.09 (OCH3), 
60.86 (C-5'), 65.33 (C-3'), 67.58 (C-2'), 69.26 (C-4'), 87.71 (C-
1'), 120.6-147.9 (11C- Ar), 166.7 (CO). MS (m / z), 471 (M+, 
53 %); C23H25N3O6S (471.5) calcd. C: 58.58, H: 5.34, N: 8.91; 





Yield 55 %; mp 270–273 °C. IR (KBr, cm–1) 3455, 3335, 1675. 
1H NMR (DMSO-d6, ppm) δ: 1.47–1.54 (m, 2H, CH2), 1.58–
1.67 (m, 2H, CH2), 2.15 (t, 2H, CH2), 2.79 (t, 2H, CH2), 3.83 
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Hz, J = 4.87 Hz, OH-C(5'), 5.22 (d, J = 4.64 Hz, OH-C(3'), 5.41 
(d, J = 5.95 Hz, OH-C(2'), 5.66 (t, J = 9.80 Hz, H-3'), 6.81 (d,  
J = 5.60 Hz, H-1'), 7.28 (d, 2H, phenyl), 8.07 (d, 2H, phenyl), 
10.15 (br, NH, D2O exchangeable). MS (m / z), 459 (M+, 38 %); 
C22H22FN3O5S (459.5) calcd. C: 57.50, H: 4.82, N: 9.14; found 




Yield 51 %; mp 273–275 °C. IR (KBr, cm–1) 3423, 3318, 1668. 
1H NMR (DMSO-d6, ppm) δ: 1.46–1.53 (m, 2H, CH2), 1.57–
1.69 (m, 2H, CH2), 2.12 (t, 2H, CH2), 2.85 (t, 2H, CH2), 3.70 
(s, OCH3), 3.82 (m, H-5', H-5"), 4.12 (m, H-4'), 4.80 (t, H-2'), 
5.14 (t, J = 5.41 Hz, J = 4.97 Hz, OH-C(5'), 5.22 (d, J = 4.46 Hz, 
OH-C(3'), 5.41 (d, J = 5.92 Hz, OH-C(2'), 5.66 (t, J = 9.78 Hz, 
H-3'), 6.86 (d, J = 5.60 Hz, H-1'), 7.28 (d, 2H, phenyl), 8.18 
(d, 2H, phenyl), 9.85 (br, NH, D2O exchangeable), 13C NMR: 
21.21, 22,56, 23.48, 24.61 (4CH2), 56.12 (OCH3), 60.85 (C-
5'), 65.36 (C-3'), 67.58 (C-2'), 69.68 (C-4'), 87.68 (C-1'), 
121.2-148.9 (11C- Ar), 167.4 (CO). MS (m / z), 471 (M+, 40 %); 
C23H25N3O6S (471.5) calcd. C: 58.58, H: 5.34, N8.91; found C 





Yield 51 %; mp 259–261 °C. IR (KBr, cm–1) 3420, 3260, 1675. 
1H NMR (DMSO-d6, ppm) δ: 1.48–1.56 (m, 2H, CH2), 1.59–
1.68 (m, 2H, CH2), 2.18 (t, 2H, CH2), 2.83 (t, 2H, CH2), 3.95 
(m, H-5'), 4.05 (m, H-6', H-6"), 4.39 (m, H-4'), 4.98 (t, H-2'), 
4.65 (br, D2O-exchangeable OH), 5.08 (br, D2O-
exchangeable OH), 5.17 (d, J = 4.82 Hz, D2O-exchangeable 
OH), 5.23 (t, J = 9.63 Hz, H-3'), 5.67 (br, D2O-exchangeable 
OH), 6.25 (d, J = 10.64 Hz, H-1'), 7.25 (d, 2H, phenyl), 8.03 
(d, 2H, phenyl), 10.35 (br, 1H, NH, D2O exchangeable). MS 
(m / z), 489 (M+, 59 %); C23H24FN3O6S (489.5) calcd. C: 56.43, 




Yield 54 %; mp 276–278 °C. IR (KBr, cm–1) 3430, 3278, 1682. 
1H NMR (DMSO-d6, ppm) δ: 1.48–1.56 (m, 2H, CH2), 1.61–
1.69 (m, 2H, CH2), 2.09 (t, 2H, CH2), 2.75 (t, 2H, CH2), 3.76 
(s, OCH3), 3.99 (m, H-5'), 4.09 (m, H-6', H-6"), 4.51 (m, H-4'), 
4.70 (br, D2O-exchangeable OH), 4.91 (t, H-2'), 5.12 (br, 
D2O-exchangeable OH), 5.19 (d, J = 4.81 Hz, D2O-
exchangeable OH), 5.28 (t, J = 9.62 Hz, H-3'), 5.69 (br, D2O-
exchangeable OH), 6.23 (d, J = 10.61 Hz, H-1'), 7.28 (d, 2H, 
phenyl), 8.05 (d, 2H, phenyl), 10.15 (br, NH, D2O 
exchangeable). 13C NMR: 22.34, 23.81, 24.12, 25.08 (4CH2), 
56.03 (OCH3), 61.45 (C-6'), 66.40 (C-3'), 67.89 (C-2'), 68.95 
(C-4'), 77.82 (C-5'), 89.71 (C-1'), 120.8–148.4 (11C-Ar), 
159.3 (C-2-pyrimidine), 165.9 (CO). MS (m / z), 485 (M+, 56 %); 
C24H27N3O6S (485.5) calcd. C: 59.36, H: 5.61, N: 8.65; found 





Yield 51 %; mp 245–247 °C. IR (KBr, cm–1) 3425, 3310, 1672. 
1H NMR (DMSO-d6, ppm) δ: 1.44–1.58 (m, 2H, CH2), 1.60–
1.72 (m, 2H, CH2), 2.19 (t, 2H, CH2), 2.79 (t, 2H, CH2), 3.93 
(m, H-5'), 4.07 (m, H-6', H-6"), 4.38 (m, H-4'), 4.98 (t, H-2'), 
4.75 (br, D2O-exchangeable OH), 5.08 (br, D2O-
exchangeable OH), 5.12 (d, J = 4.80 Hz, D2O-exchangeable 
OH), 5.19 (t, J = 9.62 Hz, H-3'), 5.71 (br, D2O-exchangeable 
OH), 6.29 (d, J = 10.62 Hz, H-1'), 7.26 (d, 2H, phenyl), 8.02 
(d, 2H, phenyl), 9.95 (br, 1H, NH, D2O exchangeable). 13C 
NMR: 22.32, 23.76, 24.19, 25.11 (4CH2), 61.53 (C-6'), 66.38 
(C-3'), 67.93 (C-2'), 70.05 (C-4'), 76.91 (C-5'), 89.67 (C-1'), 
121.1–149.6 (11C-Ar), 159.1 (C-2-pyrimidine), 166.3 (CO). 
MS (m / z), ) 489 (M+, 62 %); C23H24FN3O6S (489.5) calcd. C: 




Yield 50 %; mp 263–265 °C. IR (KBr, cm–1) 3400, 3295, 1679. 
1H NMR (DMSO-d6, ppm) δ: 1.49–1.59 (m, 2H, CH2), 1.62–
1.74 (m, 2H, CH2), 2.21 (t, 2H, CH2), 2.87 (t, 2H, CH2), 3.86 
(s, OCH3), 3.99 (m, H-5'), 4.14 (m, H-6', H-6"), 4.50 (m, H-4'), 
4.99 (t, H-2'), 4.73 (br, D2O-exchangeable OH), 5.13 (br, 
D2O-exchangeable OH), 5.18 (d, J = 4.83 Hz, D2O-
exchangeable OH), 5.25 (t, J = 9.65 Hz, H-3'), 5.75 (br, D2O-
exchangeable OH), 6.21 (d, J = 10.60 Hz, H-1'), 7.21 (d, 2H, 
phenyl), 8.11 (d, 2H, phenyl), 10.18 (br, 1H, NH, D2O 
exchangeable). MS (m / z), 485 (M+, 43 %); C24H27N3O6S 
(485.5) calcd. C: 59.36, H: 5.61, N: 8.65; found C: 59.35, H: 




A suspension of compound 3 (10 m mol) in hydrazine 
hydrate (99 %, 20 mL) was stirred under reflux for 10 h. The 
reaction mixture was allowed to cool to room temperature. 
The solid precipitated was filtered off, washed with 
ethanol, dried and crystallized from dimethylformamide to 
produce 5-(4-flutophenyl)-2-hydrazino-6,7,8,9-tetrahydro-
3H-pyrimido-[4,5-b]quinolin-4-one (9a) and  5-(4-anisyl)-2-
hydrazino-6,7,8,9-tetrahydro-3H-pyrimido[4,5-b]quinolin-




Yield 86 %; mp 319–321 °C. IR (KBr, cm–1) 3455, 1685. 1H 
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(m, 2H, CH2), 2.17 (t, 2H, CH2), 2.80 (t, 2H, CH2), 7.22 (d, 2H, 
phenyl, J = 8.4 Hz), 7.65 (d, 2H, phenyl, J = 8.5 Hz), and 9.20, 
11.50 (2br s, 2NH, D2O exchangeable). 13C.NMR: 22.69, 
23.21, 23.87, 24.59 (4CH2), 121.3–155.5 (11 C-Ar), 156.9 (C-
2-pyrimidine), 164.9 (CO). MS (m / z), 325 (M+, 78 %); 
C17H16FN5O (325.3) calcd. C: 62.75, H: 4.96, N: 21.53; found 




Yield 89 %; mp 307–309 °C. IR (KBr, cm–1) 3450, 1678. 1H 
NMR (DMSO-d6, ppm) δ: 1.51–1.61 (m, 2H, CH2), 1.64-1.79 
(m, 2H, CH2), 2.23 (t, 2H, CH2), 2.84 (t, 2H, CH2), 7.27 (d, 2H, 
phenyl, J = 8.6 Hz), 7.68 (d, 2H, phenyl, J = 8.5 Hz), and 9.35, 
11.78 (2brs, 2NH, D2O exchangeable). 13C.NMR: 22.19, 
22.51, 23.89, 24.71 (4CH2), 53.09 (OCH3). 122.3–154.5 (11 
C-Ar), 156.3 (C-2-pyrimidine), 165.6 (CO). MS (m / z), 337 
(M+, 86 %); C18H19N5O2 (337.4) calcd. C: 64.07, H: 5.67, N: 






(10a–d and 12a–d) 
A solution from each of 9a,b (10 mmol) and aldopentose / 
aldohexose (10 mmol) in a mixture of acetic anhydride, 
acetic acid (1 : 1) (50 mL) was stirred under reflux for 3–5 h 
(under TLC control). The mixture was then extracted with 
chloroform several times (150–200 mL). After removal of 
chloroform under reduced pressure the residue (the 
intermediates 10a–d, 12a–d) was followed up in the next 
step without identification. 




(11a–d and 13a–d) 
A solution from each of 10a–d or 12a–d (10 mmol) in 
solution of sodium methoxide (10 mmol) (sodium metal in 
methanol, 100 mL), was stirred at room temperature for  
24 h, and then neutralized with hydrochloric acid solution 
(pH control). The precipitate formed was filtered off, 
washed with cold water, dried and crystallized from 
ethanol (60–100 mL) to obtain 3-(glucosyl / galactosyl)-6-(4-
flurophenyl / 4-anisyl)-7,8,9,10 tetrahydro[1,2,4]triazolo 
[4',3':1,2] pyrimido[4,5-b]quinolin-5-one (11a–d) and  
3-(ribosyl / arabinosyl)-6-(4-flurophenyl / 4-anisyl)-7,8,9,10-
tetrahydro[1,2,4]triazolo[4',3':1,2]-pyrimido[4,5-b]quinolin-





Yield 48 %; mp 269–271 °C. IR (KBr, cm–1) 3450-3100, 1692. 
1H NMR (DMSO-d6, ppm) δ: 1.49–1.64 (m, 2H, CH2), 1.68–
1.79 (m, 2H, CH2), 2.26 (t, 2H, CH2), 2.90 (t, 2H, CH2), 3.56 
(m, 5OH, D2O exchangeable), 3.95 (m, 1H, H-4'), 4.21 (m, 
2H, H-5', H-5"), 4.53 (m, 1H, H-3'), 4.80 (m, 1H, H-2'), 5.69 
(m, 1H, H-1'), 7.24 (d, 2H, J = 8.4 Hz, phenyl), 7.98 (d,2H, J = 
8.5 Hz, phenyl), 10.15 (br, NH, D2O exchangeable). 13C NMR: 
22.28, 23.73, 24.21, 25.85 (4CH2), 41.35 (OCH2), 67.70, 
68.45, 69.24, 70.52 (4CH), 121.4–157.6 (13 Ar-C), 164.5 
(CO). MS (m / z), 485 (M+, 37 %); C23H24FN5O6 (485.5) calcd. 





Yield 51 %; mp 239–241 °C. IR (KBr, cm–1) 3500–3150, 1692. 
1H NMR (DMSO-d6, ppm) δ: 1.51–1.62 (m, 2H, CH2), 1.64–
1.77 (m, 2H, CH2), 2.23 (t, 2H, CH2), 2.88 (t, 2H, CH2), 3.53 
(m, 5OH, D2O exchangeable), 3.68 (s, 3H, OCH3), 3.89 (m, 
1H, H-4'), 4.20 (m, 2H, H-5', H-5"), 4.53 (m, 1H, H-3'), 4.85 
(m, 1H, H-2'), 5.70 (m, 1H, H-1'), 7.22 (d, 2H, J = 8.6 Hz, 
phenyl), 7.82 (d, 2H, J = 8.5 Hz, phenyl), 10.19 (br, 1H, NH, 
D2O exchangeable). MS (m / z), 497 (M+, 29 %); C24H24N5O7 
(497.5) calcd. C: 57.94, H: 5.47, N: 14.07; found C: 57.89, H: 





Yield 45 %; mp 253–255 °C. IR (KBr, cm–1) 3480–3120, 1692. 
1H NMR (DMSO-d6, ppm) δ: 1.47–1.61 (m, 2H, CH2), 1.65–
1.73 (m, 2H, CH2), 2.18 (t, 2H, CH2), 2.90 (t, 2H, CH2), 3.50 
(m, 5OH, D2O exchangeable), 3.87 (m, 1H, H-4'), 4.24 (m, 
2H, H-5', H-5"), 4.49 (m, 1H, H-3'), 4.72 (m, 1H, H-2'), 5.68 
(m, 1H, H-1'), 7.30 (d, 2H, J = 8.5 Hz, phenyl), 7.98 (d, 2H, J = 
8.5 Hz, phenyl), 9.80 (br, NH, D2O exchangeable). MS (m / z), 
485 (M+, 30 %); C23H24FN5O6 (485.5) calcd. C: 56.90, H: 4.98, 





Yield 54 %; mp 247–249 °C. IR (KBr, cm–1) 3440-3160, 1687. 
1H NMR (DMSO-d6, ppm) δ: 1.50–1.66 (m, 2H, CH2), 1.69–
1.80 (m, 2H, CH2), 2.28 (t, 2H, CH2), 2.92 (t, 2H, CH2), 3.55 
(m, 5OH, D2O exchangeable), 3.76 (s, 3H, OCH3), 3.85 (m, 
1H, H-4'), 4.24 (m, 2H, H-5', H-5"), 4.61 (m, 1H, H-3'), 4.75 
(m, 1H, H-2'), 5.68 (m, 1H, H-1'), 7.34 (d, 2H, J = 8.5 Hz, 
phenyl), 7.87 (d,2H, J = 8.6 Hz, phenyl), 10.05 (br, 1H, NH, 
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(4CH2), 46.08 (OCH2), 57.66 (OCH3), 67.91, 68.67, 70.14, 
71.23 (4CH), 121.6-157.2 (13 Ar-C), 165.6 (CO). MS (m / z), 
497(M+, 31 %); C24H24N5O7 (497.5) calcd. C: 57.94, H: 5.47, 





Yield 60 %; mp 262–264 °C. IR (KBr, cm–1) 3480–3180, 1689. 
1H NMR (DMSO-d6, ppm) δ: 1.51–1.63 (m, 2H, CH2), 1.66–
1.79 (m, 2H, CH2), 2.23 (t, 2H, CH2), 2.91 (t, 2H, CH2), 3.80 
(m, 4OH), 4.31 (m, 1H, H-3'), 4.62 (m, 2H, H-4', H-4"), 5.33 
(t, 1H, H-2', J = 7.6 Hz), 5.67 (d, 1H, H-1', J = 7.8 Hz), 7.28 (d, 
2H, J = 8.5 Hz, phenyl), 8.02 (d, 2H, J = 8.5 Hz, phenyl), 9.85 
(br, 1H, NH, D2O exchangeable). MS (m / z), 455 (M+, 26 %); 
C22H22FN5O5 (455.4) calcd. C: 58.01, H: 4.87, N: 15.37; found 





Yield 48 %; mp 251–253 °C. IR (KBr, cm–1) 3490–3150, 1681. 
1H NMR (DMSO-d6, ppm) δ: 1.48–1.62 (m, 2H, CH2), 1.67–
1.89 (m, 2H, CH2), 2.19 (t, 2H, CH2), 2.86 (t, 2H, CH2), 3.72 
(s, 3H, OCH3), 3.87 (m, 4OH), 4.29 (m, 1H, H-3'), 4.61 (m, 2H, 
H-4', H-4"), 5.34 (t, 1H, H-2', J =7.6 Hz), 5.66 (d, 1H, H-1', J = 
7.8 Hz), 7.28 (d, 2H, J = 8.4 Hz, phenyl), 7.96 (d, 2H, J = 8.5 Hz, 
phenyl), 9.95 (br, 1H, NH, D2O exchangeable). 13C NMR: 
22.31, 23.81, 24.56, 25.90 (4CH2), 45.19 (OCH2), 55.13 
(OCH3), 68.78, 70.34, 72.59 (3CH), 122.3–156.4 (13 Ar-C), 
165.2 (CO). MS (m / z), 467 (M+, 18 %); C23H25N5O6 (467.5) calcd. 





Yield 58 %; mp 241–242 °C. IR (KBr, cm–1) 3500–3120, 1685. 
1H NMR (DMSO-d6, ppm) δ: 1.50–1.63 (m, 2H, CH2), 1.65–
1.83 (m, 2H, CH2), 2.26 (t, 2H, CH2), 2.91 (t, 2H, CH2), 3.73 
(m, 4OH), 4.27 (m, 1H, H-3'), 4.61 (m, 2H, H-4', H-4"), 5.31 
(t, 1H, H-2', J = 7.5 Hz), 5.64 (d, 1H, H-1', J = 7.8 Hz), 7.25 (d, 
2H, J = 8.4 Hz, phenyl), 7.86 (d, 2H, J = 8.5 Hz, phenyl), 10.35 
(br, NH, D2O exchangeable). MS (m / z), 455 (M+, 21 %); 
C22H22FN5O5 (455.4) calcd. C: 58.01, H: 4.87, N: 15.37; found 





Yield 51 %; mp 239–241 °C. IR (KBr, cm–1) 3470–3160, 1683. 
1H NMR (DMSO-d6, ppm) δ: 1.51–1.62 (m, 2H, CH2), 1.64–
1.78 (m, 2H, CH2), 2.21 (t, 2H, CH2), 2.88 (t, 2H, CH2), 3.68 
(s, 3H, OCH3), 3.75 (m, 4OH), 4.27 (m, 1H, H-3'), 4.58 (m, 2H, 
H-4', H-4"), 5.27 (t, 1H, H-2', J =7.4 Hz), 5.64 (d, 1H, H-1', J = 
7.7 Hz), 7.20 (d, 2H, J = 8.5 Hz, phenyl), 7.36 (d, 2H, J = 8.6 Hz, 
phenyl), 9.85 (br, NH, D2O exchangeable). MS (m / z), 467 
(M+, 22 %); C23H25N5O6 (467.5) calcd. C: 59.09, H: 5.39, N: 
14.98; found C: 59.07, H: 5.37, N: 14.96. 
Animals  
Adult male albino rats (Harlan Sprague-Dawley), weighing 
150–180 g, were used for the evaluation of anti-
inflammatory activity. Animals were fasted for 12 hours 
before the assay. International principle and local 
regulations concerning the care of used laboratory animals 
was taken into account.[23] All animals were obtained from 
the animal house colony of the National Research Centre, 
Cairo, Egypt. The animals were acclimatized to the 
experimental room having temperature 22 ± 1 °C, controlled 
humidity conditions, and 14 : 10 h light and dark cycle. The 
rats were fed on autoclaved standard mice food pellets 
(Hindustan Lever Ltd., New Delhi) and water ad libitum. 
Anti-Inflammatory Activity 
Carrageenin-induced paw edema test was performed on 
male albino rats by using the method of Winter et al.[24] The 
animals were weighed, marked for identification and divided 
into 14 groups, each group containing 6 animals. 1 % 
carboxymethyl cellulose (CMC) was selected as vehicle to 
suspend the standard drug and test compounds. The 1st 
group was kept as control and was given the respective 
volume of vehicle (1 % CMC, oral) only. The 2nd to 13th groups 
were given a 100 mg kg–1 body mass oral dose of test 
compounds. One hour later, 0.2 mL of 1 % carrageenan 
suspension in 0.9 % NaCl solution was injected 
subcutaneously, into the subplantar tissue of the right hind 
paw of each mouse and the paw volume was measured with 
a plethysmometer (UGO Basile 7140, model-7141, Biological 
research apparatus, Italy) . The initial paw volume was 
measured within 30 s of the injection and remeasured again 
1 h, 2 h, 3 h and 4 h after administration of Carrageenan. The 
last group was administered indomethacin in a dose of 10 mg 
kg–1 orally as a standard reference.[25] The mean increase in 
paw volume was compared with that of control group and 
percent inhibition values were calculated by the formula 
given below: % anti-inflammatory activity = (Vc – Vt / Vc) × 
100. Where Vt represents the paw volume in drug treated 
animals and Vc represents the paw volume of control group 
of animals. 
In vitro Anticancer Activity in Cultured 
Cells by MTT Assay 
 
ANTITUMOR SCREENING 
Dimethyl sulfoxide (DMSO), doxorubicin, penicillin, 
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Chemical Co. (USA). RPMI-1640 medium was from Cambrex 
(USA). Fetal bovine serum (FBS) and L-glutamine were from 
Gibco Invitrogen Co. (UK). 
 
CELL CULTURES 
Some of the synthesized compounds (3a,b), (6a,b), (8a,b), 
(9a,b), (11a,b) and (13a,b) were tested for in vitro 
anticancer activity against three human tumor cell lines, 
HepG2 (human liver carcinoma), NCI-H460 (non-small cell 
lung cancer) and MCF-7 (breast adenocarcinoma) by the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay.[26] HepG2 and NCI-H460 were kindly provided 
by the National Cancer Institute (Cairo, Egypt) and MCF-7 
was obtained from the European Collection of Cell Cultures 
(Salisbury, UK). They grew as monolayers and were 
routinely maintained in RPMI-1640 medium supplemented 
with 5 % heat inactivated FBS, 2 mmol L–1 glutamine and 
antibiotics (penicillin 100 U mL–1, streptomycin 100 µg mL–1), 
at 37 °C in a humidified atmosphere containing 5 % CO2. 
Exponentially growing cells were obtained by plating  
1.5 × 105 cells mL–1, followed by 24 h incubation. The effect 
of the vehicle solvent DMSO on the growth of these cell 
lines was evaluated by exposing untreated control cells to 
the maximum concentration (0.5 %) of DMSO used in each 
assay. The effect of compounds on in vitro growth of human 
tumor cell lines was evaluated according to the procedure 
adopted by the national cancer institute (NCI, USA) by using 
sulforhodamine B as protein binding dye to assess cell 
growth.[27] Cells growing exponentially in 96-well plates 
were then exposed for 48 h to five different 
concentrations of each test compound (5, 12, 25, 50 and 
100 µmol L–1). After this exposure period, adherent cells 
were fixed, washed and stained. The bound stain was 
solubilized and the optical density (absorbance) was 
measured, and the growth inhibition of 50 % (GI50) was 
calculated.[28] Doxorubicin was used as a reference 
compound (Table 2). 
 
RESULTS AND DISCUSSION 
In continuation of our drug research program, and on the 
basis of the above considerations, original nucleoside 
analogs directed upon reverse transcriptase still aroused 
considerable interest.[29] In this study the synthetic 
pathways depicted in Schemes 1 and 2 outlines the 
chemistry of the present study. Thus, pyrimido-[4,5-
b]quinoline as the starting materials 3a,b are easily 
prepared following the well established procedure 
reported in the literature.[12] Treatment of 6-
aminothiouracil with cyclohexanone gave the 
corresponding 1,4-dihydropyridine derivatives as 
intermediates 1, 2 which in turn gave compounds 3a,b 
upon microwave irradiation at 90 °C for 20 min in DMF with 



























































































Ar = 4-F-C6H4-a, 










5a, Ar = 4-C6H4-F, R = COC6H5
5b, Ar = 4-C6H4-OCH3, R = COC6H5
5c Ar = 4-C6H4-F, R = COCH3
5d, Ar = 4-C6H4-OCH3, R = COCH3
8a, Ar = 4-C6H4-F, R1 =  H , R2 = OH
8b, Ar = 4-C6H4-OCH3, R1= H, R2 = OH
8c Ar = 4-C6H4-F, R1 = OH, R2 = H















Scheme 1. Synthesis of Deacetylated S-Glycosides of 5-Aryl-6,7,8,9-tetrahydro-3H-pyrimido-[4,5-b]quinolin-4-one  
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 Compounds 3a,b was found to be useful for the 
syntheses of the interesting S-glycosides. As a model 
experiment the alkylation of 4a,b was carried out by the 
reaction of one equivalent of methyl iodide with the 
potassium salt of 3a,b (generated in situ by the reaction of 
3a,b with alcoholic potassium hydroxide). The structure of 
the new 2-methylthioquinoline 4a,b was confirmed by all 
spectroscopic data. The 13C NMR spectrum as an example 
revealed that the corresponding signal of the C-2 (C–SCH3) 
appeared at   159 ppm. The chemical shifts in the 13C 
NMR spectrum of the 2-thioxo- (4a) and 2-methylthio-
pyrimidine in the literature[30] indicated that the site of the 
alkylation is the sulfur atom rather than the nitrogen atom 
(Scheme 1). 
 The synthetic route we used for the preparation of 2-S-
(-D-glycopyranosyl / or furanosyl)-pyrimido[4,5-b]quinoline is 
outlined in Scheme 1. The heterocycle pyrimido[4,5-
b]quinolines 3a–d was converted into its potassium salt with 
used of KOH in acetone and was stirred at room temperature 
for 15–20 hours with 2,3,5-tri-O-benzoyl--D-ribofuranosyl 
bromide or 2,3,5-tri-O-acetyl-α-D-arabinofuranose-bromide 
afforded the S-glycosylated nucleosides 5a–d in good yields. 
Thin layer chromatography (chloroform:methanol, 8:2) 
indicated the formation of the pure compounds. Also, the 
reaction of compounds 3a,b with 2,3,4,6-tetra-O-acetyl-α-D-
gluco- and galactopyranosyl bromide under the same 
conditions gave the S-glycosides 7a–d, respectively. The 
structures assignment of this product was based on their 
elemental analysis and the spectral data. 
 Deacetylation of S-nucleosides 5a–d and 7a–d 
proceeded smoothly via methanolic ammonia solution 
treatment to afford the free nucleoside mimetics 6a–d and 
8a–d in moderate yields (Scheme 1). The 1H NMR data of 
the compounds 6 and 8 revealed the absence of the acetyl 
protons and appearance of the D2O exchangeable OH-
protons at  5.19–5.46 ppm for compounds 6 and around  
4.65–5.70 ppm for compounds 8. The IR data of the 
compound 6a as a typical example also showed the 
absence of the acetyl function and the appearance of the 
characteristic OH’s band at 3400 (br) cm–1. 
 Action of hydrazine hydrate on 2-thioxopyri-
mido[4,5-b]quinoline (3a,b) in ethanol afforded 5-aryl-2-
hydrazino-2,3,6,7,8,9-hexahydro-1H-pyrimido[4,5-b]quinolin-
4-one (9a,b). Structures of these compounds are supported 
by spectral data such as IR, NMR, Mass and Elemental 
analyses. The required hydrazone intermediates 10a–d and 
12a–d were prepared by condensation of 2-hydrazino-
pyrimidoquinoline 9 with the appropriate aldohexoses  
and aldopentoses sugar (Scheme 2). Thus, Stirring of  
aryl-2-hydrazino-2,3,6,7,8,9-hexahydro-1H-pyrimido[4,5-
b]-quinolin-4-one derivatives (9a,b) with aldosugar at room 
temperature in a mixture of acetic anhydride-pyridine (1 : 1) 
afforded the respective hydrazone (10a–d, 12a–d), 
respectively as intermediates. Deprotection of the acyclic 
C-nucleosides 10a–d and 12a–d could be achieved when 
they were stirred in methanolic sodium methoxide solution 
at room temperature to give a moderate yields of  
3-(glycosyl)-6-(4-substitutedphenyl)-7,8,9,10-tetrahydro 
[1,2,4]triazolo-[4',3':1,2]pyrimido[4,5-b]quinoline-5-(1H)-one 
(11a–d, 13a–d). Structures 11a–d and 13a–d were 
confirmed by spectral and elemental analyses. Their  
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Scheme 2. Synthesis of 3-(glycosyl)-6-(4-substitutedphenyl)-7,8,9,10-tetrahydro[1,2,4]triazolo[4',3'- :1,2]pyrimido[4,5-
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protons but showed the multiplet signal supported to the 
hydroxyl group protons in the region  3.55–3.80 (D2O 
exchangeable), the signals due to the protons of the sugar 
moiety at  3.85–5.68. Also, the 13C NMR spectrum for 
compound 11d as an example showed eight lines around 
22.31–71.23 corresponding to ten sp3 carbon atoms, 
thirteen lines around 121.6–157.2 supported to the sp2 
carbon atoms and the absorption signal corresponds to the 
carbonyl group at 165.6. 
 The anti-inflammatory activity of newly synthesized 
compounds was evaluated by carrageenan-induced paw 
edema model in rats using indomethacin as a reference 
drug. Results are expressed as mean ±S.D. (Table 1). 
Differences between control and treatment groups 
evaluated for statistical significance using one way ANOVA 
followed by Tukey’s test. The test compounds administered 
1 h prior to carrageenan injection at a dose of 100 mg kg–1 
body wt. caused significant inhibition of paw edema 
volume. Most of the tested compounds showed good anti-
inflammatory activity after the 2nd hour of drug treatment 
comparable to the standard drug Indomethacin.  
Compound 6a comprising S-ribofuranozyl moiety was 
found to be most potent, showing very high activity after 
1st, 2nd, 3rd as well as 4th hour of drug, exhibited activity of 
78.6 % in comparison with Indomethacin (92.8 %). 
Compounds 8a (S-glucopyranozyl) and 13a (1,2,4-
triazoloribosyl), in addition to 4-fluorophenyl substitution 
on pyrimidoquinoline derivatives confer high anti-
inflammatory activity in the range 58.7–76.5 % compared 
to Indomethacin. Compound 11a (1,2,4-triazologlucosyl) 
showed excellent activity (83.4 %), comparable to the 
standard drug Indomethacin (85.2 %). Compound 3a with 
pyrimidoquinoline-2-thion, hydrazino derivative of 
pyrimidoquinoline 11b and 13b exhibited excellent 
inhibition of paw edema volume. Among the tested 
compounds, incorporation of electron releasing p-
methoxyphenyl on pyrimidoquinoline 3b, 6b, 8b and 9b 
resulted in a decrease of activity. 
 The effect of newly synthesized compounds was 
evaluated through the in vitro growth of three human 
tumor cell lines representing different tumor types, 
namely, human liver carcinoma (HepG2), non-small cell 
lung cancer (NCI-H460) and breast adenocarcinoma (MCF-
7), after continuous exposure for 48 h. The results 
summarized in Table (2) showed that most of the tested 
compounds exhibited significant activity compared to 
doxorubicin. Compounds 6a (GI50 = 0.01, 0.04 and  
0.08 µmol L–1), 13a (GI50 = 0.01, 0.03 and 0.06 µmol L–1) 
exhibited higher anticancer activity than that of 
doxorubicin (GI50 = 0.04, 0.05 and 0.09 µmol L–1) against the 
three tumor cell line, respectively. Such high activity of both 
compounds is attributed to the insertion of ribofuranosyl 
moiety at position 2 of compound 3a as in compound 6a, 
and the presence of more hydroxyl group of ribosyl moiety 
attached to the triazolopyrimidoquinoline as in compound 
13a. In addition to this, the presence of fluorine atom in the 
 
Table 1. Anti-inflammatory activity of tested compounds. 
Compd. 1 h 2 h 3 h 4 h 
3a 0.45 ± 0.03 (39.0) 0.47 ± 0.12(b) (62.9) 0.66 ± 0.14 (45.1) 0.59 ± 0.22(a) (53.8) 
3b 0.55 ± 0.21 (23.5) 1.04 ± 0.20 (24.2) 0.76 ± 0.08 (40.2) 0.50 ± 0.12 (28.1) 
6a 0.18 ± 0.03(b) (77.5) 0.28 ± 0.07(b) (78.6) 0.30 ± 0.05(b) (75.0) 0.48 ± 0.11(b) (61.5) 
6b 0.33 ± 0.03 (57.7) 0.26 ± 0.05(b) (76.8) 0.57 ± 0.28(b) (59.8) 0.42 ± 0.10(b) (66.9) 
8a 0.30 ± 0.04 (58.7) 0.28 ± 0.06(b) (76.5) 0.55 ± 0.29(b) (59.8) 1.03 ± 0.13 (17.8) 
8b 0.47 ± 0.11(b) (62.9) 0.27 ± 0.08(b) (75.6) 0.58 ± 0.29(b) (58.8) 0.68 ± 0.16 (44.9) 
9a 0.59 ± 0.21(a) (52.8) 0.69 ± 0.11(a) (49.2) 0.56 ± 0.29(b) (58.8) 0.76 ± 0.08 (39.2) 
9b 0.43 ± 0.07 (23.4) 0.76 ± 0.11 (32.2) 0.76 ± 0.08 (39.4) 0.75 ± 0.14(35.4) 
11a 0.50 ± 0.22(b) (58.6) 0.20 ± 0.07(b) (83.4) 0.89 ± 0.19 (34.5) 1.04 ± 0.13 (16.8) 
11b 0.36 ± 0.09 (56.2) 0.50 ± 0.22(b) (58.6) 0.76 ± 0.08 (39.2) 0.69 ± 0.11(a) (49.2) 
13a 0.40 ± 0.10(b) (67.9) 0.59 ± 0.21(a) (54.8) 0.52 ± 0.20(b) (61.7) 0.59 ± 0.21(a) (52.8) 
13b 0.69 ± 0.11(a) (49.2) 0.56 ± 0.29(b) (58.8) 0.69 ± 0.11(a) (49.2) 0.48 ± 0.11(b) (61.6) 
Control − – – – 
Indomethacin 0.05 ± 0.02(b) (92.8) 0.18 ± 0.03(b) (85.2) 0.27 ± 0.02(b) (80.6) 0.16 ± 0.03(b) (87.4) 
All values are expressed as mean ±SEM of six rats in each group. 
Values in parenthesis represent % inhibition. 
(a) Statistically significant p > 0.05 compared to control. 
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aromatic system attached to the tetrahydroquinoline 
moiety plays a significant role in the growth inhibition 
effect. Compound 11a (GI50 = 0.3, 0.6 and 0.1 µmol L–1) 
exhibited high inhibition activity on the three tumor cell 
lines, but still lower than that of doxorubicin. Compound 8a 
shows good activity due to the presence of glucopyranozyl 
moiety. On the other hand, comparing the activity of 
compounds 8a,b, 11a,b and 13a,b one can say that the 
presence of the electron withdrawing group (p-fluoro) 8a, 
11a and 13a is responsible for their higher activity while 
presence of  the electron donating group attached to the 
phenyl group lowered activity in 8b, 11b and 13b. 2-thioxo-
pyrimido[4,5-b]quinolin-4-ones 3a,b and 2-hydrazino 
pyrimido[4,5-b]quinolin-4-ones derivatives 9a,b exhibited 
moderate antitumor activity on the three tumor cell lines. 
Furthermore, it is convenient to compare the activity of  
3-(glucosyl)-5-(4-fluorophenyl)-7,8,9,10-tetrahydro[1,2,4] 
triazolo-[4',3':1,2]pyrimido[4,5-b]quinolin-5-one (11a) and 
3-(ribosyl)-5-(4-fluorophenyl)-7,8,9,10-tetrahydro[1,2,4] 
triazolo[4',3':1,2]pyrimido[4,5-b]quinolin-5-one (13a). The 
former compound derived from aldopentose was more 
active than its derivative derived from aldohexose. 
 From the obtained results we can conclude that the 
synthesized compounds were evaluated for anti-
inflammatory and anticancer activity. In vivo anti-
inflammatory activity of C- and S-glycoside of pyrimido[4,5-
b]quinoline derivatives on carrageenan-induced rat paw 
edema model identified compounds 6a and 11a as a potent 
antiinflammatory agents. The cytotoxicity of synthesized 
compounds was evaluated against human liver carcinoma 
(HepG2), non-small cell lung cancer (NCI-H460) and breast 





exhibited the maximum growth inhibition activity toward 
the three human cancer cell lines, higher than that of the 
reference doxorubicin. 
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